Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Regulation of latent stage differentiation through central carbon metabolism and ubiquitination

Award Number: R01AI172823
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/05/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

Regulation of latent stage differentiation through central carbon metabolism and ubiquitination - Project summary Toxoplasma latently infects approximately 30% of the human population and is refractory to acute stage therapies. Latent Toxoplasma can act as a reservoir for acute stage reactivation in immunocompromised individuals and can cause progressive blindness in otherwise healthy individuals. Thus, latent stages are clinically important, but currently untreatable. Drug resistance is likely due to changes in the metabolism of latent stages, but what these are remain a complete mystery. Furthermore, latent Toxoplasma is exposed to different nutritional environments when infecting its target tissue types – muscle and the central nervous system (CNS) – and the impact this has on Toxoplasma latency is not understood. We have found that changes in carbon sources, that mimic muscle and CNS trigger Toxoplasma differentiation into latent forms. We then performed a whole-genome CRISPR screen and identified select Toxoplasma carbon catabolic enzymes that are required for differentiation and furthermore, identified a role for ubiquitination in metabolic adaptation and differentiation into latent forms. These background studies form the basis for developing a comprehensive understanding of Toxoplasma metabolism during latency and understanding how metabolic rewiring is linked to differentiation through regulation by ubiquitination. The specific aims of this program are to: Aim 1: Define the metabolic pathways required for differentiation and persistence of latent Toxoplasma. We will determine the role of select enzymes (identified in CRISPR screen) required for utilization of carbon sources that mimic brain and muscle and their impact on differentiation in vitro and in vivo. This will determine how metabolism of latent and acute stages differs and how this is linked to environmental sensing and differentiation. Aim 2: Determine the role of ubiquitination in the regulation of differentiation into latent forms. Define the composition, biochemical activity and structure of an E3 ubiquitin ligase complex that is important for differentiation into latent forms, thus determining how ubiquitination regulates differentiation. Aim 3: Define how ubiquitination regulates metabolism and differentiation into latent forms. We have identified likely substrates of the E3 ubiquitination machinery and will define their function in regulation of both metabolism and differentiation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $520,009 )
2026	2026	THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE				AUS	Allergy and Infectious Diseases Research	000	4	1/10/2026	NON-COMPETING CONTINUATION	$520,009
														Subtotal = $520,009

Issue Date FY: 2025 ( Subtotal = $504,409 )
2025	2025	THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE				AUS	Allergy and Infectious Diseases Research	000	3	12/20/2024	NON-COMPETING CONTINUATION	$504,409
														Subtotal = $504,409

Issue Date FY: 2024 ( Subtotal = $520,009 )
2024	2024	THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE	VIC			AUS	Allergy and Infectious Diseases Research	000	2	12/7/2023	NON-COMPETING CONTINUATION	$468,007
2024	2024	THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE				AUS	Allergy and Infectious Diseases Research	001	2	4/15/2024	NON-COMPETING CONTINUATION	$52,002
														Subtotal = $520,009

Issue Date FY: 2023 ( Subtotal = $522,010 )
2023	2023	THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE	VIC			AUS	Allergy and Infectious Diseases Research	000	1	12/2/2022	NEW	$417,608
2023	2023	THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE	VIC			AUS	Allergy and Infectious Diseases Research	001	1	9/21/2023	NEW	$104,402
														Subtotal = $522,010

Grand Total All Awards = $2,066,437

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Regulation of latent stage differentiation through central carbon metabolism and ubiquitination

Award Number: R01AI172823

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/05/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer